Abstract #0365
Comparison of the Central Effects of Ketamine and the NR2B-Selective NMDA Receptor Antagonist Traxoprodil Using Pharmacological MRI in Conscious Rats
Haiying Tang 1 , Yu-Wen Li 1 , Matthew Fronheiser 1 , Daniel Kukral 1 , Harold Malone 1 , Adrienne Pena 1 , Gabriel Tobon 2 , Kurex Sidik 1 , Patrick Chow 1 , Linda Bristow 1 , Wendy Hayes 1 , and Feng Luo 1
1
Bristol-Myers Squibb, Princeton, NJ, United
States,
2
InviCRO,
Boston, MA, United States
Major depressive disorder (MDD), a leading cause of
disability globally, has an enormous social and economic
impact. Improvements in the efficacy of antidepressant
therapy are needed. Ketamine is a nonselective NMDA
antagonist which has been reported to have
antidepresseant effects in patients with MDD.
Significant efforts have been reported in the
development of NR2B subtype-selective antagonists, to
minimize adverse side effects observed with nonselective
NMDA antagonists. In the present study we implemented
pharmacological MRI (phMRI) in conscious rats to map the
central effects of ketamine and traxoprodil, and to
study the neurocircuitry that might attribute to the
antidepressant effects.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
